Introduction
deaths
ADVERSE EVENT
Since being designated by the WHO as a pandemic in March 2019, SARS-CoV-2 has infected more than 540 million people and was responsible for 6 million deaths in June 2022 (The development of dendritic cell (DC)–based vaccines is an innovative vaccine that can overcome existing problems. DC–based vaccines utilize the ability of DCs as antigen-presenting cells (APCs) to induce a human immune system oriented to T-cell immunity (In previous studies, both preclinical and interim analysis results of phase I and II clinical trials found that this vaccine has good potential. In short-term observations (3 months), no serious adverse event (SAE) was found in the subjects of phase I and II clinical trials. In addition, autologous DC–based vaccines loaded with SARS CoV-2 S-protein (AV-COVID-19 or Nusantara vaccine) can induce adequate T-cell immunity well. The vaccine can also form an antibody response (